Ebola Hemorrhagic Fever as a Public Health Emergency of International Concern; a Review Article
Archives of Academic Emergency Medicine,
Vol. 3 No. 1 (2015),
1 February 2015
,
Page 3-7
https://doi.org/10.22037/aaem.v3i1.256
Abstract
Ebola hemorrhagic fever (EHF) was first reported in 1976 with two concurrent outbreaks of acute viral hemorrhagic fever centered in Yambuku (near the Ebola River), Democratic Republic of Congo, and also in Nzara, Sudan. The current outbreak of the Ebola Virus was started by reporting the first case in March 2014 in the forest regions of southeastern Guinea. Due to raising infection rates of over 13,000% within a 6-month period, now is considered as a global public health emergency and in August 8, 2014 the World Health Organization (WHO) has declared the epidemic to be a Public Health Emergency of International Concern. With more than 5000 involved cases and also nearly 3000 deaths, this event has turned to the largest and most dangerous Ebola virus outbreak in all around the world. Based on above mentioned, the present article aimed to review the virologic characteristics, transmission, clinical manifestation, diagnosis, treatment, and prevention of Ebola virus disease.- Hemorrhagic fever
- Ebola
- health
- emergency responders
- virology
- infection control
How to Cite
References
Laupland KB, Valiquette L. Ebola virus disease. Can J Infect Dis Med Microbiol. 2014;25(3):128-9.
Koenig KL, Majestic C, Burns MJ. Ebola Virus Disease: Essential Public Health Principles for Clinicians. West J Emerg Med. 2014;[In press].
Okware S, Omaswa F, Zaramba S, et al. An outbreak of Ebola in Uganda. Trop Med Int Health. 2002;7(12):1068-75.
McCoy CE, Lotfipour S, Chakravarthy B, Schultz C, Barton E. Emergency Medical Services Public Health Implications and Interim Guidance for the Ebola Virus in the United States. West J Emerg Med. 2014; 15(7):723-7.
Fowler RA, Fletcher T, Fischer WA, et al. Caring for Critically Ill Patients with Ebola Virus Disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190(7):733-7.
Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014;55:1-9.
Stahelin RV. Membrane Binding and Bending in Ebola VP40 Assembly and Egress. Front Microbiol. 2014;5:300.
MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis. 2010;16(12):1969-72.
Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007–2008. PLoS One. 2012;7(12):e52986.
Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ. 2014;349:g5079.
Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438(7068):575-6.
Fauci AS. Ebola—underscoring the global disparities in health care resources. N Engl J Med. 2014;371:1084-6.
Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196(Supplement 2):S142-S7.
Feldmann H, Geisbert TW. Ebola haemorrhagic fever. The Lancet. 2011;377(9768):849-62.
Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(suppl 3):S810-S6.
Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8:411-40.
Saijo M, Niikura M, Ikegami T, Kurane I, Kurata T, Morikawa S. Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin Vaccine Immunol. 2006;13(4):444-51.
Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Supplement 2):S390-S9.
Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. The Lancet. 2003;362(9400):1953-8.
Choi JH, Croyle MA. Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment. Biodrugs. 2013;27(6):565-83.
Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-5.
Elshabrawy HA, Fan J, Haddad CS, et al. Identification of a Broad-Spectrum Antiviral Small Molecule against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay. J Virol. 2014;88(8):4353-65.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21.
Woodrow CJ, Eziefula AC, Agranoff D, et al. Early risk assessment for viral haemorrhagic fever: experience at the Hospital for Tropical Diseases, London, UK. J Infect. 2007;54(1):6-11.
- Abstract Viewed: 283 times
- PDF Downloaded: 3482 times
- HTML Downloaded: 81 times
